About Tandem Diabetes Care, Inc. - Common Stock (TNDM)
Tandem Diabetes Care is a medical device company that specializes in the development and manufacturing of innovative products for people with diabetes. The company focuses on creating advanced insulin delivery systems, including insulin pumps and related software solutions, designed to improve the management of diabetes for individuals who rely on insulin therapy. By leveraging cutting-edge technology, Tandem aims to enhance the user experience, offering features such as automated insulin delivery and seamless data integration, ultimately helping patients achieve better health outcomes and greater convenience in their daily lives. Read More
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 20.3% in the afternoon session after the company reported third-quarter results that surpassed analyst expectations for both revenue and earnings per share.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.6% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Tandem Diabetes Care (TNDM) beat Q3 2025 earnings and revenue estimates, driving a 16% stock surge. The company reported strong sales growth and improved margins.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.2% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 5.1% in the morning session after analyst projections for its third-quarter 2025 earnings pointed to a year-on-year revenue decline.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Certification from Insight Assurance, affirming Tandem’s company-wide commitment to cybersecurity, data protection, and operational integrity. As Tandem continues to expand internationally, the ISO/IEC 27001:2022 certification strengthens its position in regulated markets and simplifies compliance for partners and healthcare providers worldwide.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 6% in the afternoon session after investor concerns were sparked by a disappointing financial outlook from peer DexCom. DexCom, a major company in the glucose monitoring market, reported its third-quarter financial results. Although the company's earnings and revenue surpassed targets, its stock fell sharply by around 11% to 12%. The drop was triggered after company executives provided a growth forecast for 2026 that might not meet Wall Street's expectations and also signaled a lower margin forecast. This negative outlook from a key industry player appeared to create wider concerns, weighing on shares of related companies like Tandem Diabetes.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States.* This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes worldwide. In the U.S., the updated software for the FreeStyle Libre 3 Plus sensor integration is preloaded on all new t:slim X2 pump shipments, and is also available to all eligible t:slim X2 pump users through a software update.† The Company plans to launch early-access programs for the integrated technologies internationally before the end of the year, with scaling commercial availability to follow in 2026.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 1.6% in the afternoon session after the company announced a positive update on a clinical study for its Control-IQ system. The study, conducted in France, aimed to assess the real-world safety, performance, and quality of life benefits for individuals with Type 1 Diabetes using the system. Positive findings from such studies could increase confidence in the product's effectiveness. The move also occurred amid a favorable long-term view of the industry, with a report projecting the U.S. insulin pump market would grow to $2.58 billion by 2033, driven by rising diabetes rates and new technology. This backdrop of potential growth came even as the company faced challenges, having recently reported a revenue increase of 8.5% year-over-year but missing earnings per share estimates.
Looking back on healthcare technology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Tandem Diabetes (NASDAQ:TNDM) and its peers.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
